Adil Aftab: Anticoagulation in CKD – Key Updates from the 2026 ESC Guidelines
Adil Aftab, Postgraduate Trainee at People’s University of Medical and Health Sciences for Women, Nawabshah, shared a post on LinkedIn:
“Anticoagulation in CKD: Key Updates from the 2026 ESC Guidelines
The 2026 ESC Guidelines for the management of cardiovascular disease and chronic kidney disease highlight the importance of individualized anticoagulation decisions in patients with chronic kidney disease (CKD) and either venous thromboembolism (VTE) or atrial fibrillation (AF).
- Renal function matters: Anticoagulant selection should be tailored according to eGFR and bleeding/thromboembolic risk.
- AF: Factor Xa inhibitors are generally preferred in patients with eGFR 30–59 mL/min/1.73 square meters.
- Advanced CKD: At eGFR below 30, treatment becomes increasingly individualized, with careful consideration of bleeding risk and available evidence.
- Dialysis: Decisions regarding anticoagulation require particularly careful risk–benefit assessment because evidence remains limited.
- VTE: Factor Xa inhibitors may be preferred over LMWH or VKA in selected CKD stages, while very advanced CKD requires individualized decision-making.
This guideline reinforces an important clinical principle: anticoagulation in CKD is not ‘one size fits all.’ Renal function, indication, thromboembolic risk, bleeding risk, and the specific anticoagulant all need to be considered.
A valuable update for clinicians involved in Internal Medicine, Cardiology, Nephrology, and Hematology.”
Stay updated with Hemostasis Today.
-
Oct 16, 2026, 13:59Aya Akmal Amin: Antiphospholipid Syndrome Management and Risk Stratification
-
Oct 16, 2026, 13:10Emanuel Sueldo: CAHT 2026 Celebrates Scientific Progress and Team Achievements
-
Oct 16, 2026, 13:05Maha Othman: Queen’s Health Sciences Advances CAT Risk Models and Pediatric ISTH-BAT Cut-Offs
-
Oct 16, 2026, 13:03Thrombosis Awareness Must Lead to Timely Action – Roche
-
Oct 16, 2026, 12:49Wolfgang Miesbach: 5-Year CBDR Data Confirms Emicizumab Safety and Efficacy in Hemophilia A
-
Oct 16, 2026, 12:40Edward Lee Carter: How Factor XI Inhibition Could Transform Anticoagulation Therapy
-
Oct 16, 2026, 12:40Marc Carrier: Looking Ahead to ISTH 2027 in Vancouver
-
Oct 16, 2026, 12:30Bob Lempke: How One Blood Donation Can Save Up to Three Lives
-
Oct 16, 2026, 12:30Why VWF Therapies Belong on the EU Critical Medicines List – EHC